| 1975: recognition of non-A, non-B hepatitis (HCV) as a specific entity, |
| 1989: HCV specifically identified, |
| 1991-1992: initial approval and use of interferon (IFN) therapy for HCV, |
| 1993: HCV genome organization and polyprotein processing defined, |
| 1996: first three-dimensional structure of HCV protein, the NS3-4A protease, |
| 1997: first infectious clone of HCV isolated, |
| 1998: ribavirin added to interferon therapy, |
| 1999: replicon system developed enabling in vitro study of the virus replication, |
| 2003: development of functional HCV pseudoparticles, |
| 2003: initial proof-of-concept of HCV replication utilizing a protease inhibitor, |
| 2004: first reports of occult HCV infection (OCI), |
| 2005: recombinant infectious HCV produced in tissue culture, |
| 2009: IL28B polymorphisms identified that affect viral responses to therapy, |
| 2011: approval of the first direct acting antivirals (DAA) agents, |
| 2013: complete HCV life cycle defined in humanized mice, |
| 2013: all oral therapy utilizing DAA approved. |
